Description
Deoxynojirimycin (19130-96-2) inhibits α-glucosidase I and II.1,2 Inhibits human immunodeficiency virus envelope glycoprotein-mediated membrane fusion at the CXCR4 binding step.3 May be used to produce an affinity ligand for purifying glucosidase 1.4 Deoxynojirimycin was used to inhibit ER glucosidases I and II allowing for the discovery of a second mechanism for deglucosylation of N-linked oligosaccharides in PhaR1.7, a mouse lymphoma cell line.5
Chemical Properties
White Crystalline Solid
Uses
An inhibitor of α-glucosidase I and II
Uses
Deoxynojirimycin inhibits mammalian glucosidase 1. As well, it inhibits intestinal and lysosmal alpha-glucosidases, beta-glucosidase from sweet almonds, pancreatic alpha-amylase and amyloglucosidase.
Definition
ChEBI: An optically active form of 2-(hydroxymethyl)piperidine-3,4,5-triol having 2R,3R,4R,5S-configuration.
Biological Activity
Inhibitor of glucosidase I (K i = 2.1 mM) and II (K i = 7 mM).
References
1) Fuhrmann et al. (1985), Inhibitors of oligosaccharide processing; Biochim. Biophys, Acta, 825 95
2) Hughs and Rudge (1994), Deoxynojirimycin: synthesis and biological activity; Nat. Prod. Rep., 11 135
3) Papandreou et al. (2002), The alpha-glucosidase inhibitor 1-deoxynojirimycin blocks human immunodeficiency virus envelope glycoprotein-mediated membrane fusion at the CXCR4 binding step; Mol. Pharmacol., 61 186
4) Hettkamp et al. (1984), Purification by affinity chromatography of glucosidase I, an endoplasmic reticulum hydrolase involved in the processing of asparagine-linked oligosaccharides; Eur. J. Biochem., 142 85
5) Suh et al. (1992), Identification of a novel mechanism for the removal of glucose residues from high mannose-type oligosaccharides; J. Biol. Chem., 267 21671